Shopping Cart
- Remove All
- Your shopping cart is currently empty
GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $32 | In Stock | |
5 mg | $73 | In Stock | |
10 mg | $107 | In Stock | |
25 mg | $227 | In Stock | |
50 mg | $449 | In Stock | |
100 mg | $656 | In Stock | |
500 mg | $1,360 | Backorder | |
1 mL x 10 mM (in DMSO) | $123 | In Stock |
Description | GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR. |
In vitro | METHODS: RCC cells Caki-1 (VHL wild type) and 786-O (VHL mutant) were treated with GW6471 (12.5-100 µM) for 72 h. Cell viability was measured using MTT assay. |
In vivo | METHODS: To assay in vivo antitumor activity, GW6471 (20 mg/kg) was injected intraperitoneally every two days for four weeks into Nu/Nu mice bearing the RCC tumor Caki-1. RESULTS: In vivo treatment of xenograft mouse model with PPARα antagonist GW6471 attenuated RCC growth. [2] |
Alias | GW 6471 |
Molecular Weight | 619.67 |
Formula | C35H36F3N3O4 |
Cas No. | 880635-03-0 |
Smiles | CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F |
Relative Density. | 1.204 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 16.67 mg/mL (26.9 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+90% Saline: 0.25 mg/mL (0.4 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.